Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3052726 | 1.00 | KMT2A (0.51) | KMT2ALMNAHSD17B10OPRK1POLB | |
| SCHEMBL3052442 | 1.00 | KMT2A (0.51) | KMT2ALMNAHSD17B10OPRK1POLB | |
| SCHEMBL24931077 | 0.90 | KMT2A (0.61) | KMT2APOLBMEP1BHIF1ASIGMAR1 | |
| SCHEMBL24931076 | 0.90 | KMT2A (0.61) | KMT2APOLBMEP1BHIF1ASIGMAR1 | |
| SCHEMBL30559566 | 0.88 | SMN1; SMN2 (0.55) | KMT2ALMNAPOLBMEP1BHIF1A | |
| Hydrochloric Acid SCHEMBL22614732 | 0.86 | SMN1; SMN2 (0.54) | KMT2ALMNAPOLBMEP1BHIF1A | |
| SCHEMBL5076506 | 0.85 | OPRK1 (0.62) | KMT2ALMNAHSD17B10OPRK1GRIN2B | |
| SCHEMBL6170323 | 0.85 | LMNA (0.43) | LMNAALDH1A1MAPT | |
| SCHEMBL22829007 | 0.81 | KDM4E (0.49) | KMT2ALMNAHSD17B10ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL22828989 | 0.80 | KDM4E (0.48) | KMT2ALMNAHSD17B10ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081845-A1 | Process for Production of Optically Active Benzylamine Derivatives | ALPS PHARMACEUTICAL INC. CO., LTD. (JP) | 2010-04-01 | — | — | US | disclosed |
| US-20100081845-A1 | Process for Production of Optically Active Benzylamine Derivatives | ALPS PHARMACEUTICAL INC. CO., LTD. (JP) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081845-A1 | Process for Production of Optically Active Benzylamine Derivatives | RAB27A, HTR7, ALKBH1 | KMT2A 2717/4885LMNA 2714/4885HSD17B10 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.